CARE Ratings (NSE:CARERATING) Research & Development: ₹0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:CARERATING CARE Ratings Ltd NSE:CARERATING
84 GF Score
Price ₹1,749.20
GF Value ₹1,719.38
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is CARE Ratings Research & Development?

CARE Ratings NSE:CARERATING +1.10% 84 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:CARERATING with a GF Score™ of 84/100 and a GF Value™ of ₹1,719.38 (Fairly Valued). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. CARE Ratings's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

CARE Ratings  (NSE:CARERATING) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

CARE Ratings Research & Development Related Terms

CARE Ratings Research & Development Historical Data

* Premium members only.

The historical data trend for CARE Ratings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARE Ratings Research & Development Chart

CARE Ratings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CARE Ratings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:CARERATING
84GF Score
CARE Ratings Ltd NSE:CARERATING
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CARE Ratings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
CARE Ratings (NSE:CARERATING) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on CARE Ratings and its competitors.
Is CARE Ratings' Research & Development too high?
CARE Ratings' current Research & Development is ₹0 Mil. Overall, CARE Ratings has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does CARE Ratings' Research & Development compare to SPGI and CME?
CARE Ratings' Research & Development of ₹0 Mil can be compared against companies in the Capital Markets industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Capital Markets company?
A good Research & Development depends on the Capital Markets industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on CARE Ratings and its competitors. CARE Ratings's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARE Ratings stock overvalued right now?
Based on GuruFocus' analysis, CARE Ratings (NSE:CARERATING) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,719.38, compared to a current price of ₹1,749.20 — trading 1.7% above its estimated fair value. The current Research & Development is ₹0 Mil. CARE Ratings' overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For CARE Ratings (NSE:CARERATING), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CARE Ratings (NSE:CARERATING) Overvalued in 2026?

Based on GuruFocus' analysis, CARE Ratings stock appears to be overvalued. The current stock price of ₹1,749.20 is trading 1.7% above its estimated GF Value™ of ₹1,719.38. GuruFocus considers CARE Ratings to be Fairly Valued.

Key valuation signals for NSE:CARERATING:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹1,719.38 vs. price of ₹1,749.20 (1.7% above fair value)
  • GF Score™: 84/100 with 1 warning sign

No single metric tells the full story. See the NSE:CARERATING stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CARE Ratings Business Description

Other Exchanges 534804:India
Address Somaiya Hospital Road, Off Eastern Express Highway, 4th Floor, Godrej Coliseum, Sion (East), Mumbai, MH, IND, 400 022
CARE Ratings Ltd provides various credit ratings that helps corporates to raise capital for their various requirements and assists the investors to form an informed investment decision based on the credit risk and their own risk-return expectations. The company works in Bank Loan Ratings; Capital Market Instruments, Including NCDs/ Bonds/ Hybrids/ CPs/CDs, etc; Structured Finance Ratings; Monitoring Agency Services for Equity Capital; Rating of REITs /InvITs; Resolution Plan Ratings; Recovery Ratings; Issuer Ratings. The company's segment includes Ratings and related services; and Others. The company generates majority of revenue from Ratings and related services. The company has presence in India, and Outside India. It generates majority of revenue from India.
84GF Score

Get the complete analysis for NSE:CARERATING

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,749.20
Price
₹1,719.38
GF Value